CLAIMS

I/We Claim

1. A pharmaceutical composition for oral administration comprising
   a. a therapeutically effective amount of GLP receptor agonist or pharmaceutically acceptable salt or derivatives thereof,
   b. one or more medium chain fatty acid based permeation enhancers with aromatic functional group, and
   c. one or more medium chain fatty acid based permeation enhancers without aromatic functional group.
2. The pharmaceutical composition as claimed in claim 1, further comprising one or more basifier.
3. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein GLP receptor agonist is semaglutide.
4. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein medium chain fatty acid based permeation enhancers with aromatic functional group is in amount of 25 mg to 200mg.
5. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein medium chain fatty acid based permeation enhancers with aromatic functional group is salcaprozate sodium.
6. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein medium chain fatty acid based permeation enhancers without aromatic functional group is selected from group consisting of sodium caprate or sodium caprylate or combinations thereof, optionally wherein sodium caprate or sodium caprylate or combinations thereof is in an amount of 25mg to 800mg.
7. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein said composition does not contains binder.
8. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein said pharmaceutical composition is tablet.
9. The pharmaceutical composition as claimed in claim 8, wherein said tablet is prepared by direct compression method.

10. The pharmaceutical composition as claimed in claim 1, wherein said composition further comprises one or more additional active ingredient.
11. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein AUC_{0-t} (ngxh/mL) for said pharmaceutical composition is 1.5 times or more compare to AUC_{0-t} (ngxh/mL) for reference product Rybelsus in single dose fasted study in human volunteers.
12. The pharmaceutical composition as claimed in claim 1 or claim 2, wherein Cmax (ng/mL) for said pharmaceutical composition is 1.5 times or more compare to Cmax (ng/mL) for reference product Rybelsus in single dose fasted study in human volunteers.
13. The pharmaceutical composition as claimed in claim 2, wherein basifier is calcium carbonate.
14. The pharmaceutical composition as claimed in claim 1, comprising
    a. a therapeutically effective amount of semaglutide,
    b. 25 mg to 200mg of salcaprozate sodium, and
    c. 25mg to 800mg of sodium caprate or sodium caprylate or combinations thereof.
15. The pharmaceutical composition as claimed in claim 2, comprising
    a. a therapeutically effective amount of semaglutide,
    b. salcaprozate sodium,
    c. sodium caprate or sodium caprylate or combinations thereof, and
    d. calcium carbonate.